Cargando…
Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out‐Of‐Pocket Expenses? Insights From ARTEMIS
BACKGROUND: Persistence to P2Y12 inhibitors after myocardial infarction (MI) remains low. Out‐of‐pocket cost is cited as a factor affecting medication compliance. We examined whether a copayment intervention affected 1‐year persistence to P2Y12 inhibitors and clinical outcomes. METHODS AND RESULTS:...
Autores principales: | Rymer, Jennifer A., Kaltenbach, Lisa A., Peterson, Eric D., Cohen, David J., Fonarow, Gregg C., Choudhry, Niteesh K., Henry, Timothy D., Cannon, Christopher P., Wang, Tracy Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673662/ https://www.ncbi.nlm.nih.gov/pubmed/36250667 http://dx.doi.org/10.1161/JAHA.122.026421 |
Ejemplares similares
-
Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs
por: Doll, Jacob A., et al.
Publicado: (2020) -
Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial
por: Rymer, Jennifer A., et al.
Publicado: (2023) -
Patients’ out-of-pocket expenses analysis of presurgical teledermatology
por: de Mello-Sampayo, Felipa
Publicado: (2019) -
Discussing patients’ insurance and out-of-pocket expenses during GPs’ consultations
por: Victoor, A., et al.
Publicado: (2019) -
MEDICAL MARIJUANA LAWS AND OUT OF POCKET EXPENSES AT END OF LIFE
por: Bhagianadh, Divya, et al.
Publicado: (2022)